We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Analytical Performance Evaluated for Troponin T Gen 5 Assay

By LabMedica International staff writers
Posted on 05 Sep 2019
Print article
Image: The Elecsys Troponin T Gen 5 STAT assay (Photo courtesy of Roche Diagnostics).
Image: The Elecsys Troponin T Gen 5 STAT assay (Photo courtesy of Roche Diagnostics).
Increased blood concentrations of cardiac troponin (cTn) I and T are indicative of myocardial injury and are the preferred biomarkers for diagnosing acute myocardial infarction (AMI). The diagnosis of AMI requires a rise and/or fall in serial cTn measurements, in addition to other clinical features.

The introduction of high-sensitivity assays has enabled the rapid detection of subtle changes in cTn and facilitated earlier decision-making in the management of patients with suspected AMI, compared with less sensitive contemporary assays. These newer assays which can measure cTn concentrations 5 to 10 times lower than current assays and do so with improved analytical imprecision.

A team of Medical Scientists collaborating with the University of California San Diego Health (San Diego, CA, USA) analyzed the performance of the Elecsys Troponin T Gen 5 STAT assay. This assay is an electrochemiluminescence sandwich immunoassay, which uses two antibodies to form a sandwich complex with cTnT. A biotinylated monoclonal anti-cTnT-specific antibody and a monoclonal anti-cTnT-specific antibody labeled with ruthenium react to form a sandwich complex. Precision was evaluated per Clinical and Laboratory Standards Institute (CLSI) EP05-A2 using lithium-heparin plasma/quality control samples on Roche cobas e 411/cobas e 601 analyzers.

The scientists reported that the coefficients of variation (CV) for repeatability/intermediate precision were 0.7–5.6%/1.4–10.3% (cobas e 411; mean cardiac troponin T [cTnT]: 7.3–9,341 ng/L) and 0.7–3.0%/1.5–6.4% (cobas e 601; mean cTnT: 7.4–9,455 ng/L). There was no cross-reactivity with skeletal muscle troponin T (≤ 10,000 ng/L), skeletal muscle troponin I (≤ 100,000 ng/L), cardiac troponin I (≤ 10,000 ng/L), or human troponin C (≤ 80,000 ng/L). No interference was observed with biotin (≤ 20 ng/mL) or 34 drugs. The specified limit of blank and limit of detection were 3 ng/L and 5 ng/L, respectively, on the cobas e 411 analyzer, and 2.5 ng/L and 3 ng/L, respectively, on the cobas e 601 analyzer.

The authors concluded that the Elecsys TnT Gen 5 STAT assay demonstrated good analytical performance on cobas e 411 and cobas e 601 analyzers, with a CV of ≤ 10% at the 99th percentile URL. These findings support the routine use of the assay in clinical laboratories in the USA. The study was published in the August 2019 issue of the journal Clinica Chimica Acta.

Related Links:
University of California San Diego Health

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.